Fig. 1From: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily betterResponse of 13 melanoma patients on phase Ib A. Spider plot showing percent change from baseline over time. BÂ Best overall response for each patient depicted by waterfall plot. Asterisk denotes progression in patient in non-target lesionsBack to article page